First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial in Advanced Solid Tumors with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
April 27, 2015 – Alligator Bioscience AB today announced that the first patient was dosed early last week in the recently initiated phase 1 clinical trial of the immuno-oncology antibody ADC-1013. ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immune-stimulatory receptor found on antigen-presenting cells such as dendritic cells.
The clinical phase 1 trial is a first-in-human trial for patients with advanced solid tumor disease. Dr. Per Norlén, Chief Medical Officer at Alligator Bioscience, commented that “we are very pleased to confirm that dosing of the first patient was successful. The interest for participation in our first-in-human trial has been massive, allowing dosing of the first patient at Uppsala University Hospital, Sweden, within 3 weeks of starting recruitment. ADC-1013 was well tolerated and not associated with any significant adverse reactions. Currently we have opened 2 clinical sites, and expect all 5 sites to be active shortly.”
As mentioned in a previous press release April 7, the study will enroll up to 40 patients during the dose escalation and expansion phases at five centers in the United Kingdom, Denmark and Sweden.